Testing a new cancer drug for blood cancers that stopped responding to other treatments

Plain-English translation of NCT04830137 on ClinicalTrials.gov ↗ · Source last updated March 2026 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing a new medication called for people with certain blood cancers (like leukemia and lymphoma) that have stopped responding to previous treatments. The study will first figure out the safest dose, and then test how well the medication works at different doses in patients with different types of blood cancer.

Patients with advanced blood cancers often run out of treatment options that work. This medication uses a new approach to target cancer cells, and researchers hope it may help people whose cancers have become resistant to existing therapies.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have been diagnosed with a relapsed or refractory B-cell blood cancer (such as chronic lymphocytic leukemia, lymphoma, or Waldenström macroglobulinemia)
your cancer has stopped responding to at least 2 prior standard treatments (or at least 1 treatment if you have certain types of cancer)
you have measurable disease that can be tracked on scans or blood tests
you are in generally good health with adequate organ and bone marrow function

You likely don't qualify if…

you have active autoimmune disease affecting your blood cells (like autoimmune hemolytic anemia)
you are currently taking warfarin or similar blood thinners
you have had recent radiation therapy within 2 weeks before starting the study
you cannot swallow capsules or have conditions that would prevent the medication from being absorbed properly
you have a bleeding disorder or condition that increases your risk of severe bleeding

What participation looks like

In the first part of the study, you would take the medication by mouth at gradually increasing doses while researchers closely monitor your safety and how your body tolerates it. In the second part, researchers will test specific doses in groups of patients with different cancer types to see which dose works best. You will have regular visits for blood tests, scans, and check-ins with your doctor to track how you are responding and watch for any side effects.

AI-generated summary from trial data · Jun 3, 2026 · Not medical advice

Trial locations(16 sites)

United States

City of Hope, Duarte, California

University of California Irvine, Orange, California

University of California San Francisco Medical Center, San Francisco, California

Sarah Cannon Research Institute at Colorado Blood Cancer Institute, Denver, Colorado

Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida